This is a preview of subscription content, log in via an institution to check access.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transpl. 2007;40:105–10.
Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transpl. 2011;17:1490–6.
Dai Z, Liu J, Zhang WG, Cao X, Zhang Y, Dai Z. Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients. Mol Clin Oncol. 2016;4:667–71.
Gorin NC, Labopin M, Czerw T, Pabst T, Blaise D, Dumas PY, et al. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission— better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: a retrospective study from the acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation(EBMT). Cancer 2017;123:824–31.
Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transpl. 2016;22:1844–50.
Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, et al. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation. Int J Hematol. 2019;109:197–205.
Jiang JL, Gao WH, Wang LN, Wan M, Wang L, Hu J. Post-transplantation cyclophosphamide, tacrolimus and low-dose ATG as GVHD prophylaxis for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a single arm phase II study. Front Med. 2021;8:630160.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123:3664–71.
Wang L, Wang LN, Zhou JF, Gao WH, Jiang CH, Tang W, et al. Low-dose Decitabine monotherapy reverses mixed chimerism in adult patients after allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen: a pilot phase II study. Front Med. 2021;8:627946.
Author information
Authors and Affiliations
Contributions
JH and LW was responsible for designing the clinical trial and revising the manuscript. JjL, MC and LnW collected the clinical data and wrote the report. WhG contributed to data extraction and provided feedback on the report. Ming Wan did the statistical analysis.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jiang, Jl., Chen, M., Wang, Ln. et al. Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study. Bone Marrow Transplant 57, 843–845 (2022). https://doi.org/10.1038/s41409-022-01643-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01643-4
- Springer Nature Limited